Faculty
Ramaswamy Govindan.jpg

Ramaswamy Govindan, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Lung cancer
  • Cancer genomics

Contact

  • 314-362-5737 (tel)
  • 314-747-7405 (secretary)
  • 314-362-3895 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Manuscripts

  • Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
    Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT
    J Thorac Oncol 2017 Jul 5; [Epub ahead of print]
  • TRAC(ERx)-ing Lung Cancer Evolution
    Devarakonda S, Govindan R
    Ann Oncol 2017 Jun 19; [Epub ahead of print]
  • Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
    Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC
    Br J Cancer 2017 Jun 6;116(12):1505-1512
  • Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute cooperative group studies
    Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X
    J Clin Oncol 2017 May 11; [Epub ahead of print]
  • Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
    Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2017 Apr;15(4):504-535
  • An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
    Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA
    Lung Cancer 2017 Feb;104:126-130
  • Efficacy and safety results from a phase II, placebo-controlled study of onartuzumab plus first-line platinum-doublet chemotherapy for advanced squamous cell non-small-cell lung cancer
    Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR
    Clin Lung Cancer 2017 Jan;18(1):43-49
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
    Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR
    SCRX16-001 investigators

    Lancet Oncol 2017 Jan;18(1):42-51
  • Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non-small cell lung cancer
    Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F
    J Thorac Oncol 2017 Jan;12(1):145-151
  • Systemic treatment of brain metastases
    Waqar SN, Morgensztern D, Govindan R
    Hematol Oncol Clin North Am 2017 Feb;31(1):157-176
  • Next-generation sequencing of lung cancers: lessons learned and future directions
    Devarakonda S, Masood A, Govindan R
    Hematol Oncol Clin North Am 2017 Feb;31(1):1-12
  • Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer
    Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI
    J Clin Oncol 2016 Dec;34(34):4079-4085
  • Consolidation chemotherapy following weekly carboplatin-paclitaxel based chemoradiation for locally advanced non-small cell lung cancer is associated with improved overall and disease-free survival
    Weiner AA, Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, Fergus S, Trovo M, Baggstrom MQ, Morgensztern D, Govindan R, Waqar SN, Bradley JD, Robinson CG
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E441-E442
  • Patterns of care and survival for early versus delayed radiation therapy (RT) in limited-stage small cell lung cancer (LS-SCLC): A review of the National Cancer Data Base
    Robinson CG, Samson P, Bradley JD, Roach MC, DeWees TA, Waqar SN, Baggstrom MQ, Govindan R, Higgins KA, Simone CB 2nd, Grover S, Puri V, Morgensztern D
    Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E436-E437
  • Adjuvant chemotherapy for patients with T2N0M0 NSCLC
    Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V
    J Thorac Oncol 2016 Oct;11(10):1729-35
  • Clinician perspectives on current issues in lung cancer drug development
    Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Janne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM
    J Thorac Oncol 2016 Sep;11(9):1387-96
  • NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2016 Jul;14(7):825-36
  • Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
    Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G, Artyomov MN, Schreiber R, Govindan R, Meyerson M
    Cancer Genome Atlas Research Network

    Nat Genet 2016 Jun;48(6):607-16
  • Delayed nausea and vomiting from carboplatin doublet chemotherapy
    Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R
    Acta Oncol 2016 Jun;55(6):700-4
  • Clinical implications of genomic discoveries in lung cancer
    Swanton C, Govindan R
    N Engl J Med 2016 May 12;374(19):1864-1873
  • Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?
    Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR
    J Thorac Oncol 2016 Apr;11(4):453-474
  • PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer
    Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E
    J Clin Oncol 2016 Mar 20;34(9):953-62
  • NCCN guidelines insights: non-small cell lung cancer, version 4.2016
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2016 Mar;14(3):255-64
  • Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study
    Ou SI, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW
    J Clin Oncol 2016 Mar 1;34(7):661-668
  • A phase I trial of temsirolimus and pemetrexed in patients with advanced non-small cell lung cancer
    Waqar SN, Baggstrom MQ, Morgensztern D, Williams K, Rigden C, Govindan R
    Chemotherapy 2016;61(3):144-7
  • Patterns and functional implications of rare germline variants across 12 cancer types
    Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee T, Ning J, Tripathi P, Zhang Q, Niu B, Ye K, Schmidt HK, Fulton RS, McMichael JF, Batra P, Kandoth C, Bharadwaj M, Koboldt DC, Miller CA, Kanchi KL, Eldred JM, Larson DE, Welch JS, You M, Ozenberger BA, Govindan R, Walter MJ, Ellis MJ, Mardis ER, Graubert TA, DiPersio JF, Ley TJ, Wilson RK, Goodfellow PJ, Raphael BJ, Chen F, Johnson KJ, Parvin JD, Ding L
    Nat Commun 2015 Dec 22;6:10086
  • ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer
    Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Janne PA, Gandara DR, Ramalingam SS, Vokes EE
    Clin Cancer Res 2015 Dec 15;21(24):5439-5444
  • Immunogenicity of influenza vaccination in patients with cancer
    Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R
    Am J Clin Oncol 2015 Dec 14; [Epub ahead of print]
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data
    Paesmans M, Garcia C, Wong CY, Patz EF Jr, Komaki R, Eschmann S, Govindan R, Vansteenkiste J, Meert AP, de Jong WK, Altorki NK, Higashi K, Van Baardwijk A, Borst GR, Ameye L, Lafitte JJ, Berghmans T, Flamen P, Rami-Porta R, Sculier JP
    Eur Respir J 2015 Dec;46(6):1751-61
  • Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer
    Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY
    Cancer 2015 Dec 1;121(23):4165-4172
  • Brain metastases at presentation in patients with non-small cell lung cancer
    Waqar SN, Waqar SH, Trinkaus K, Gadea CA, Robinson CG, Bradley J, Watson MA, Puri V, Govindan R, Morgensztern D
    Am J Clin Oncol 2015 Sep 3; [Epub ahead of print]
  • Clonal evolution: multiregion sequencing of esophageal adenocarcinoma before and after chemotherapy
    Devarakonda S, Govindan R
    Cancer Discov 2015 Aug;5(8):796-8
  • Genomic alterations in lung adenocarcinoma
    Devarakonda S, Morgensztern D, Govindan R
    Lancet Oncol 2015 Jul;16(7):e342-51
  • Bone metastases in lung cancer. potential novel approaches to therapy
    Vicent S, Perurena N, Govindan R, Lecanda F
    Am J Respir Crit Care Med 2015 Oct 1;192(7):799-809
  • Non-small cell lung cancer, version 6.2015
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2015 May;13(5):515-24
  • Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline
    Bezjak A, Temin S, Franklin G, Giaccone G, Govindan R, Johnson ML, Rimner A, Schneider BJ, Strawn J, Azzoli CG
    J Clin Oncol 2015 Jun 20;33(18):2100-5
  • Overcoming resistance to targeted therapy for lung cancer
    Govindan R
    N Engl J Med 2015 Apr 30;372(18):1760-1761
  • Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future
    Rajagopalan K, Govindan R
    J Thorac Dis 2015 Mar;7(3):217-9
  • Repeatability of 18F-FDG PET/CT in advanced non-small cell lung cancer: prospective assessment in 2 multicenter trials
    Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Govindan R, Torigian DA, Karp JS, Michael Yu JQ, Subramaniam RM, Halvorsen RA, Siegel BA
    ACRIN 6678 and MK-0646-008 Research teams

    J Nucl Med 2015 Aug;56(8):1137-43
  • Exploratory subset analysis of African Americans from the Pointbreak Study: pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIb/IV nonsquamous non-small-cell lung cancer
    Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK
    Clin Lung Cancer 2015 May;16(3):200-8
  • ALCHEMIST: bringing genomic discovery and targeted therapies to early-stage lung cancer
    Gerber DE, Oxnard GR, Govindan R
    Clin Pharmacol Ther 2015 May;97(5):447-450
  • New insights into the molecular profile of lung adenocarcinoma and implications for therapy
    Ganesh B, Devarakonda S, Govindan R
    Expert Rev Anticancer Ther 2015 Apr;15(4):361-4
  • Postoperative radiotherapy for pathologic n2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the national cancer data base
    Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V
    J Clin Oncol 2015 Mar 10;33(8):870-6
  • Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies
    Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, Govindan R, Koustensis A, Barker S, Obasaju C
    Lung Cancer 2015 Mar;87(3):232-240
  • Clinical next-generation sequencing in patients with non-small cell lung cancer
    Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R
    Cancer 2015 Feb 15;121(4):631-9
  • Quality of life analyses from the randomized, open-label, phase III Pointbreak Study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIb or IV nonsquamous non-small-cell lung cancer
    Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P
    J Thorac Oncol 2015 Feb;10(2):353-9
  • Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
    Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R
    J Thorac Oncol 2015 Jan;10(1 Suppl 1):S1-S63
  • PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer
    Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ
    J Thorac Oncol 2015 Jan;10(1):134-42
  • Non-small cell lung cancer, version 1.2015
    Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2014 Dec;12(12):1738-61
  • Cancer. Attack of the clones Full Text | Reprint
    Govindan R
    Science 2014 Oct 10;346(6206):169-70
  • CHESS improves cancer caregivers' burden and mood: Results of an eHealth RCT
    DuBenske LL, Gustafson DH, Namkoong K, Hawkins RP, Atwood AK, Brown RL, Chih MY, McTavish F, Carmack CL, Buss MK, Govindan R, Cleary JF
    Health Psychol 2014 Oct;33(10):1261-72
  • Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer
    White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA
    Genome Biol 2014 Aug 13;15(8):429
  • The oligometastatic state -- separating truth from wishful thinking
    Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, Weichselbaum R
    Nat Rev Clin Oncol 2014 Sep;11(9):549-57
  • TP53 mutations and lung cancer: not all mutations are created equal
    Govindan R, Weber J
    Clin Cancer Res 2014 Sep 1;20(17):4419-21
  • Comprehensive molecular profiling of lung adenocarcinoma
    The Cancer Genome Atlas Research Network (Contributors include: Govindan R)
    Nature 2014 Jul 31;511(7511):543-550
  • cDNA hybrid capture improves transcriptome analysis on low-input and archived samples
    Cabanski CR, Magrini V, Griffith M, Griffith OL, McGrath S, Zhang J, Walker J, Ly A, Demeter R, Fulton RS, Pong WW, Gutmann DH, Govindan R, Mardis ER, Maher CA
    J Mol Diagn 2014 Jul;16(4):440-51
  • A phase I study of temsirolimus and thoracic radiation in non-small-cell lung cancer
    Waqar SN, Robinson C, Bradley J, Goodgame B, Rooney M, Williams K, Gao F, Govindan R
    Clin Lung Cancer 2014 Mar;15(2):119-23
  • Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing
    Hagemann IS, Govindan R, Javidan-Nejad C, Pfeifer JD, Cottrell CE
    J Thorac Oncol 2014 Feb;9(2):e12-6
  • Summary report from the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting
    Morgensztern D, Govindan R
    Clin Lung Cancer 2014 Jan;15(1):16-20
  • PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
    Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R
    J Clin Oncol 2013 Dec 1;31(34):4349-57
  • DGIdb: mining the druggable genome
    Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, Koval J, Das I, Callaway MB, Eldred JM, Miller CA, Subramanian J, Govindan R, Kumar RD, Bose R, Ding L, Walker JR, Larson DE, Dooling DJ, Smith SM, Ley TJ, Mardis ER, Wilson RK
    Nat Methods 2013 Dec;10(12):1209-10
  • Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
    Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC
    J Clin Oncol 2013 Nov 10;31(32):4105-14
  • An emerging place for lung cancer genomics in 2013
    Daniels MG, Bowman RV, Yang IA, Govindan R, Fong KM
    J Thorac Dis 2013 Oct;5(Suppl 5):S491-S497
  • Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3
    Yin Y, Betsuyaku T, Garbow JR, Miao J, Govindan R, Ornitz DM
    Cancer Res 2013 Sep 15;73(18):5730-41
  • Molecularly targeted therapies in locally advanced non-small-cell lung cancer
    Devarakonda S, Morgensztern D, Govindan R
    Clin Lung Cancer 2013 Sep;14(5):467-72
  • Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma
    Devarakonda S, Morgensztern D, Govindan R
    Oncology (Williston Park) 2013 Sep;27(9):899-906
  • Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer
    Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju C
    J Thorac Oncol 2013 Oct;8(10):1308-16
  • Non-small cell lung cancer, version 2.2013
    Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2013 Jun 1;11(6):645-53; quiz 653
  • Biostatistics primer: what a clinician ought to know - prognostic and predictive factors
    Simms L, Barraclough H, Govindan R
    J Thorac Oncol 2013 Jun;8(6):808-13
  • Genomic landscape of squamous cell carcinoma of the lung
    Morgensztern D, Devarakonda S, Govindan R
    Am Soc Clin Oncol Educ Book 2013;33:348-53
  • Genomics of squamous cell lung cancer
    Rooney M, Devarakonda S, Govindan R
    Oncologist 2013 Jun;18(6):707-16
  • Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology
    Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M
    J Natl Compr Canc Netw 2013 May 1;11(5):562-76
  • A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer
    Waqar SN, Gopalan PK, Williams K, Devarakonda S, Govindan R
    Chemotherapy 2013;59(1):8-13
  • An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial
    Gustafson DH, Dubenske LL, Namkoong K, Hawkins R, Chih MY, Atwood AK, Johnson R, Bhattacharya A, Carmack CL, Traynor AM, Campbell TC, Buss MK, Govindan R, Schiller JH, Cleary JF
    Cancer 2013 May 1;119(9):1744-51
  • Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site
    Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G, Govindan R
    J Thorac Oncol 2013 Jul;8(7):860-5
  • Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer
    Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR
    J Thorac Oncol 2013 Mar;8(3):369-72
  • The era of big trials is over
    Rooney M, Govindan R
    Lancet Oncol 2013 Jan;14(1):12-4
  • Small cell lung cancer
    Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M
    J Natl Compr Canc Netw 2013 Jan 1;11(1):78-98
  • Cancer gene sequencing: ethical challenges and promises
    Devarakonda S, Govindan R, Hammerman PS
    Virtual Mentor 2012 Nov 1;14(11):868-72
  • Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer
    Socinski MA, Govindan R, Spigel D
    Clin Adv Hematol Oncol 2012 Oct;10(10 Suppl 18):1-16
  • Genomic landscape of non-small cell lung cancer in smokers and never-smokers
    Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK
    Cell 2012 Sep 14;150(6):1121-34
  • Comprehensive genomic characterization of squamous cell lung cancers
    Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M
    Nature 2012 Sep 27;489(7417):519-25
  • Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a Surveillance, Epidemiology, and End Results (SEER) survey from 1998 to 2003
    Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R
    J Thorac Oncol 2012 Oct;7(10):1479-84
  • Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer
    Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R
    J Thorac Oncol 2012 Oct;7(10):1485-9
  • Non-small cell lung cancer
    Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM
    J Natl Compr Canc Netw 2012 Oct 1;10(10):1236-71
  • Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology
    Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, Ansari R, Govindan R, Bruetman D, Fisher W, Breen T, Johnson CS, Yu M, Einhorn L, Hanna N
    Ann Oncol 2012 Jul;23(7):1730-8
  • Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial
    Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, Papai ZS, Karaseva N, Thongprasert S, Portulas ED, von Pawel J, Zhang K, Selaru P, Tye L, Chao RC, Govindan R
    J Clin Oncol 2012 Jun 10;30(17):2070-8
  • MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer
    Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, Sezhiyan A, Pfeifer J, Li YF, Hua X, Wang Y, Yang P, You M
    Carcinogenesis 2012 May;33(5):1046-54
  • Optimising therapy for EGFR-addicted NSCLC: just the start
    Govindan R, Subramanian J
    Lancet Oncol 2012 Mar;13(3):216-7
  • A roundup of articles published in recent months
    Subramanian J, Waqar S, Morgensztern D, Govindan R
    J Thorac Oncol 2012 Mar;7(3):626-8
  • Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial
    Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE
    Clin Lung Cancer 2012 Mar;13(2):123-8
  • Malignant pleural mesothelioma
    Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC
    J Natl Compr Canc Netw 2012 Jan 1;10(1):26-41
  • Recent advances in lung cancer: summary of presentations from the 47th annual meeting of the American Society of Clinical Oncology (ASCO) 2011
    Subramanian J, Waqar SN, Morgensztern D, Govindan R
    J Thorac Oncol 2012 Jan;7(1):260-5
  • Targeted therapy in lung cancer: lessons learned from past experiences
    Subramanian J, Waqar SN, Govindan R
    J Thorac Oncol 2011 Nov;6(11 Suppl 4):S1786-8
  • Summary of presentation from the targeted therapy in lung cancer meeting
    Govindan R
    J Thorac Oncol 2011 Nov;6(11 Suppl 4):S1757
  • Small cell lung cancer
    Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr
    J Natl Compr Canc Netw 2011 Oct;9(10):1086-113
  • A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer
    Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R
    J Thorac Oncol 2011 Oct;6(10):1757-1760
  • Hope without hype: EML4-ALK inhibition for treatment of lung cancer
    Govindan R
    Lancet Oncol 2011 Oct;12(11):983-4
  • A survey of Internet utilization among patients with cancer
    Castleton K, Fong T, Wang-Gillam A, Waqar MA, Jeffe DB, Kehlenbrink L, Gao F, Govindan R
    Support Care Cancer 2011 Aug;19(8):1183-90
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407
    Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE
    J Clin Oncol 2011 Aug 10;29(23):3120-5
  • Annual review of advances in non-small cell lung cancer research: a report for the year 2010
    Stinchcombe TE, Bogart J, Veeramachaneni NK, Kratzke R, Govindan R
    J Thorac Oncol 2011 Aug;6(8):1443-1450
  • A roundup of recently published articles relevant to thoracic oncology
    Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jul;6(7):1295-7
  • Biostatistics primer: what a clinician ought to know: hazard ratios
    Barraclough H, Simms L, Govindan R
    J Thorac Oncol 2011 Jun;6(6):978-82
  • Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer
    Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J
    J Thorac Oncol 2011 Apr;6(4):790-5
  • Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer
    Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R
    J Thorac Oncol 2011 Apr;6(4):786-9
  • Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer
    Morgensztern D, Pennell NA, Subramanian J, Govindan R
    Clin Lung Cancer 2011 Mar;12(2):94-9
  • Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer
    Boehmer L, Waqar S, Butler S, Sezhiyan A, Govindan R
    J Thorac Oncol 2011 Mar;6(3):645-9
  • Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer
    Subramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Feb;6(2):399-403
  • Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology: Focus on non-small cell lung cancer (2010)
    Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan R
    J Thorac Oncol 2011 Jan;6(1):227-232
  • Best of the Month: a round up of articles published in recent months
    Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):223-226
  • Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials
    Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R
    J Thorac Oncol 2011 Jan;6(1):98-102
  • Radiotherapy
    Baggstrom MQ, Govindan R
    J Thorac Oncol 2010 Dec;5(12 Suppl 6):S476-7
  • Vaccines and immunotherapy for non-small cell lung cancer
    Morgensztern D, Goodgame B, Govindan R
    J Thorac Oncol 2010 Dec;5(12 Suppl 6):S463-5
  • Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer
    Govindan R
    J Thorac Oncol 2010 Dec;5(12 Suppl 6):S433
  • Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group
    Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N
    J Thorac Oncol 2010 Dec;5(12):2008-11
  • Influenza vaccination in patients with cancer: an overview
    Boehmer LM, Waqar SN, Govindan R
    Oncology (Williston Park) 2010 Nov 15;24(12):1167-70
  • Thymic malignancies
    Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC
    J Natl Compr Canc Netw 2010 Nov 1;8(11):1302-1315
  • Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer
    Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J
    J Thorac Oncol 2010 Nov;5(11):1755-63
  • Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Subramanian J, Morgensztern D, Govindan R
    Clin Lung Cancer 2010 Sep 1;11(5):311-319
  • Time to move beyond clinical and pathologic classification of BAC
    Pennell NA, Govindan R
    Oncology (Williston Park) 2010 Sep;24(10):900-1
  • Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic
    Wang-Gillam A, Williams K, Novello S, Gao F, Scagliotti GV, Govindan R
    J Clin Oncol 2010 Aug 20;28(24):3803-7
  • Best of the month: a roundup of articles published in recent months
    Morgensztern D, Govindan R
    J Thorac Oncol 2010 Aug;5(8):1305-7
  • Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website
    Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, Govindan R
    J Thorac Oncol 2010 Aug;5(8):1116-9
  • Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
    Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR
    J Thorac Oncol 2010 Aug;5(8):1279-1284
  • Non-small cell lung cancer
    Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC
    J Natl Compr Canc Netw 2010 Jul;8(7):740-801
  • Annual review of advances in lung cancer clinical research: a report for the year 2009
    Stinchcombe TE, Bogart J, Wigle DA, Govindan R
    J Thorac Oncol 2010 Jul;5(7):935-9
  • One more fallen star--ZODIAC and its implications
    Stinchcombe TE, Govindan R
    Lancet Oncol 2010 Jul;11(7):604-5
  • A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117
    Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H
    Int J Radiat Oncol Biol Phys 2010 Jun 1;77(2):367-72
  • Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Velcheti V, Morgensztern D, Govindan R
    Biologics 2010 May 25;4:83-90
  • Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117
    Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H
    J Clin Oncol 2010 May 10;28(14):2475-80
  • Biostatistics primer: what a clinician ought to know: subgroup analyses
    Barraclough H, Govindan R
    J Thorac Oncol 2010 May;5(5):741-6
  • Lung cancer in never smokers: a new hot area of research
    Govindan R
    Lancet Oncol 2010 Apr;11(4):304-5
  • [A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]
    Govindan R
    Zhongguo Fei Ai Za Zhi 2010 Apr;13(4):363-9
  • INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS
    Govindan R
    J Clin Oncol 2010 Feb 10;28(5):713-5
  • Chemotherapy: continued lack of progress in SCLC
    Subramanian J, Govindan R
    Nat Rev Clin Oncol 2010 Feb;7(2):77-8
  • A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer
    Govindan R
    Clin Lung Cancer 2010 Jan;11(1):8-12
  • Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey
    Morgensztern D, Ng SH, Gao F, Govindan R
    J Thorac Oncol 2010 Jan;5(1):29-33
  • Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis
    Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R
    J Thorac Oncol 2010 Jan;5(1):23-8
  • Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
    Scagliotti G, Govindan R
    Oncologist 2010;15(5):436-46
  • Lung cancer in "never-smokers": a unique entity
    Subramanian J, Govindan R
    Oncology (Williston Park) 2010 Jan;24(1):29-35
  • Improving survival for stage IV non-small cell lung cancer: a Surveillance, Epidemiology, and End Results survey from 1990 to 2005
    Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R
    J Thorac Oncol 2009 Dec;4(12):1524-1529
  • Summary of presentations from the Ninth Annual Targeted Therapies in Lung Cancer Symposium
    Govindan R
    J Thorac Oncol 2009 Nov;4(11 Suppl 3):S1045
  • Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, Pallares C, Burgess R, Tye L, Selaru P, Wang E, Chao R, Govindan R
    Br J Cancer 2009 Nov 3;101(9):1543-8
  • Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients
    Goodgame B, Viswanathan A, Zoole J, Gao F, Miller CR, Subramanian J, Meyers BF, Patterson AG, Govindan R
    J Thorac Oncol 2009 Nov;4(11):1370-4
  • Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009)
    Goodgame B, Stinchcombe TE, Simon G, Wozniak A, Govindan R
    J Thorac Oncol 2009 Oct;4(10):1293-1300
  • Progress in the treatment of metastatic non-small-cell lung cancer: slow but steady!
    Ramnath N, Govindan R
    Clin Lung Cancer 2009 Jul;10(4):260-1
  • Treatment rationale and study design for the PointBreak Study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
    Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC
    Clin Lung Cancer 2009 Jul;10(4):252-6
  • Summary of selected presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium
    Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R
    J Thorac Oncol 2009 Jul;4(7):930-935
  • Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer
    Keswani RN, Early DS, Edmundowicz SA, Meyers BF, Sharma A, Govindan R, Chen J, Kohlmeier C, Azar RR
    Gastrointest Endosc 2009 Jun;69(7):1210-7
  • Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study
    Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, Germonpre P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M
    J Clin Oncol 2009 May 20;27(15):2523-9
  • Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma
    Velcheti V, Kasai Y, Viswanathan AK, Ritter J, Govindan R
    J Thorac Oncol 2009 Apr;4(4):559
  • Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
    Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA
    Support Care Cancer 2009 Mar;17(3):307-13
  • Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies
    Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE
    Cancer Chemother Pharmacol 2009 Feb;63(3):451-8
  • A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104
    Govindan R, Wang X, Baggstrom MQ, Burdette-Radoux S, Hodgson L, Vokes EE, Green MR
    J Thorac Oncol 2009 Feb;4(2):220-6
  • A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors
    Morgensztern D, Baggstrom MQ, Pillot G, Tan B, Fracasso P, Suresh R, Wildi J, Govindan R
    Chemotherapy 2009;55(6):441-5
  • Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study
    Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W, Masters G, White A, Stover D, Yu M, Hanna N
    J Thorac Oncol 2009 Jan;4(1):93-96
  • Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology
    Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L
    J Clin Oncol 2008 Dec 10;26(35):5755-60
  • Small cell, big problem! Stem cells, root cause?
    Subramanian J, Govindan R
    Clin Lung Cancer 2008 Sep;9(5):252-3
  • Tracheo-esophageal fistula with bevacizumab after mediastinal radiation
    Goodgame B, Veeramachaneni N, Patterson A, Govindan R
    J Thorac Oncol 2008 Sep;3(9):1080-1
  • Locally advanced non-small cell lung cancer: the past, present, and future
    Govindan R, Bogart J, Vokes EE
    J Thorac Oncol 2008 Aug;3(8):917-28
  • Esophageal carcinoma with celiac nodal metastases; curative or palliative?
    Trovo M, Bradley J, El Naqa I, Foster E, Meyers B, Govindan R, Patterson A
    J Thorac Oncol 2008 Jul;3(7):751-5
  • Molecular genetics of lung cancer in people who have never smoked
    Subramanian J, Govindan R
    Lancet Oncol 2008 Jul;9(7):676-82
  • Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
    Lynch TJ Jr, Blumenschein GR Jr, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A
    J Thorac Oncol 2008 Jun;3(6 Suppl 2):S107-12
  • Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer
    Einhorn LH, Bonomi P, Bunn PA Jr, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS
    J Thorac Oncol 2008 May;3(5):545-55
  • Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology
    Morgensztern D, Govindan R
    Clin Lung Cancer 2008 Mar;9 Suppl 2:S57-61
  • Adjuvant chemotherapy for lung cancer: cisplatin doublets only?
    Morgensztern D, Govindan R
    J Natl Compr Canc Netw 2008 Mar;6(3):277-84
  • Non-small cell lung cancer
    Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE
    J Natl Compr Canc Netw 2008 Mar;6(3):228-69
  • EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong T, Morgensztern D, Govindan R
    J Thorac Oncol 2008 Mar;3(3):303-10
  • A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer
    Goodgame B, Viswanathan A, Miller CR, Gao F, Meyers B, Battafarano RJ, Patterson A, Cooper J, Guthrie TJ, Bradley J, Pillot G, Govindan R
    Am J Clin Oncol 2008 Feb;31(1):22-8
  • Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV
    J Clin Oncol 2008 Feb 1;26(4):650-6
  • The effect of FDG-PET on the stage distribution of non-small cell lung cancer
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R
    J Thorac Oncol 2008 Feb;3(2):135-9
  • Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer
    Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA, Govindan R
    J Thorac Oncol 2008 Feb;3(2):130-4
  • A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer
    Morgensztern D, Perry MC, Govindan R
    Acta Oncol 2008;47(1):152-3
  • A Phase I trial of weekly docetaxel and topotecan for solid tumors
    Lim WT, Baggstrom MQ, Read W, Fracasso PM, Govindan R
    Acta Oncol 2008;47(2):311-5
  • A phase I study of bexarotene and rosiglitazone in patients with refractory cancers
    Read WL, Baggstrom MQ, Fracasso PM, Govindan R
    Chemotherapy 2008 Jun 18;54(3):236-241
  • A phase I study of docetaxel and bexarotene
    Wildi JD, Baggstrom MQ, Suresh R, Read W, Fracasso PM, Govindan R
    Chemotherapy 2008;54(2):125-30
  • Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer
    Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK
    J Thorac Oncol 2008 Jan;3(1):37-45
  • Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer
    Blackstock AW, Govindan R
    J Clin Oncol 2007 Sep 10;25(26):4146-52
  • Radiation-induced myonecrosis presenting as a subcutaneous mass after combined modality therapy for non-small cell lung cancer
    Velcheti V, Gilstrap E, Bradley J, Govindan R
    J Thorac Oncol 2007 Sep;2(9):875-6
  • Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC)
    Subramanian J, Velcheti V, Gao F, Govindan R
    J Thorac Oncol 2007 Sep;2(9):827-30
  • Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D, Govindan R
    Clin Cancer Res 2007 Aug 1;13(15 Pt 2):s4602-5
  • Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
    Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS
    Clin Cancer Res 2007 Aug 1;13(15 Pt 2):s4583-8
  • Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen
    Velcheti V, Govindan R
    Lung Cancer 2007 Aug;57(2):240-2
  • Second-line therapy for esophageal cancer
    Martin MG, Govindan R, Morgensztern D
    Expert Rev Anticancer Ther 2007 Jun;7(6):871-6
  • EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity
    Vikis H, Sato M, James M, Wang D, Wang Y, Wang M, Jia D, Liu Y, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Yang P, Wiest JS, Fain PR, Schwartz AG, Gazdar A, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Viswanathan A, Govindan R, Minna J, Anderson MW, You M
    Cancer Res 2007 May 15;67(10):4665-70
  • PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer
    Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL
    Oncol Rep 2007 Apr;17(4):853-7
  • Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer
    Subramanian J, Velcheti V, Baggstrom MQ, Govindan R
    J Thorac Oncol 2007 Apr;2(4):373
  • Lung cancer in never smokers: a review
    Subramanian J, Govindan R
    J Clin Oncol 2007 Feb 10;25(5):561-70
  • Metastatic cancer involving bladder: a review
    Velcheti V, Govindan R
    Can J Urol 2007 Feb;14(1):3443-8
  • A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing
    Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR
    Clin Cancer Res 2007 Feb 1;13(3):986-93
  • Drug delivery and toxicity of adjuvant chemotherapy for non-small cell lung cancer (NSCLC): Washington University experience
    Velcheti V, Viswanathan AK, Baggstrom MQ, Govindan R
    Acta Oncol 2007;46(6):869-70
  • Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1
    Wang M, Vikis HG, Wang Y, Jia D, Wang D, Bierut LJ, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Yang P, Wiest JS, Fain PR, Schwartz AG, Gazdar A, Minna J, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Liu Y, Viswanathan A, Govindan R, Anderson MW, You M
    Cancer Res 2007 Jan 1;67(1):93-9
  • Hedgehog signaling pathway and lung cancer
    Velcheti V, Govindan R
    J Thorac Oncol 2007 Jan;2(1):7-10
  • Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer
    Walker MS, Vidrine DJ, Gritz ER, Larsen RJ, Yan Y, Govindan R, Fisher EB
    Cancer Epidemiol Biomarkers Prev 2006 Dec;15(12):2370-7
  • A gene expression signature predicts survival of patients with stage I non-small cell lung cancer
    Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, Sun Z, Szoke J, Gerald WL, Watson M, Govindan R, You M
    PLoS Med 2006 Dec;3(12):e467
  • Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
    Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, Bonomi P
    J Clin Oncol 2006 Nov 20;24(33):5253-8
  • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
    Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH
    J Clin Oncol 2006 Nov 1;24(31):5025-33
  • A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report
    Pillot GA, Read WL, Hennenfent KL, Marsh S, Gao F, Viswanathan A, Cummings K, McLeod HL, Govindan R
    J Thorac Oncol 2006 Nov;1(9):972-8
  • Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies
    Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Bolejack V, Ghalie R
    J Clin Oncol 2006 Oct 20;24(30):4848-54
  • Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
    Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J
    J Clin Oncol 2006 Oct 1;24(28):4539-44
  • Insulin-like growth factor and lung cancer
    Velcheti V, Govindan R
    J Thorac Oncol 2006 Sep;1(7):607-10
  • The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey
    Velcheti V, Viswanathan A, Govindan R
    J Thorac Oncol 2006 Jun;1(5):501
  • Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
    Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J
    Lung Cancer 2006 Sep;53(3):331-7
  • Novel formulations of taxanes: a review. Old wine in a new bottle?
    Hennenfent KL, Govindan R
    Ann Oncol 2006 May;17(5):735-49
  • Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474
    Morgensztern D, Govindan R
    Expert Rev Anticancer Ther 2006 Apr;6(4):545-51
  • Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial
    Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH
    Lung Cancer 2006 Apr;52(1):93-7
  • Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review
    Pillot G, Siegel BA, Govindan R
    J Thorac Oncol 2006 Feb;1(2):152-9
  • Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report
    Subramanian J, Pillot G, Narra V, Govindan R
    Lung Cancer 2006 Feb;51(2):257-9
  • Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer
    Hammoud ZT, Kesler KA, Ferguson MK, Battafarrano RJ, Bhogaraju A, Hanna N, Govindan R, Mauer AA, Yu M, Einhorn LH
    Dis Esophagus 2006;19(2):69-72
  • CASE 3. Benign pleural nodules in a patient with esophageal cancer
    Lim WT, Govindan R
    J Clin Oncol 2006 Jan 20;24(3):525
  • A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Govindan R, Lim WT, Arquette MA, Goodner SA, Fears CL, Mortimer JE, Fracasso PM
    Oncol Rep 2006 Jan;15(1):123-7
  • A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer
    Bogart JA, Govindan R
    Clin Lung Cancer 2006 Jan;7(4):285-7
  • The role of docetaxel in N2 locally advanced non-small-cell lung cancer
    Pillot G, Govindan R
    Clin Lung Cancer 2005 Dec;7 Suppl 3:S87-92
  • Clinical-pathologic conference in general thoracic surgery: Cardiac lymphoma
    Battafarano R, Lee R, Patterson GA, Sundt T, Gutierrez F, Dehdashti F, Ritter J, Govindan R, Bradley J
    J Thorac Cardiovasc Surg 2005 Sep;130(3):870-4
  • Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer
    Viswanathan A, Pillot G, Govindan R
    Lung Cancer 2005 Dec;50(3):417-8
  • Recent advances and future perspectives in the management of lung cancer
    Krupnick AS, Kreisel D, Hope A, Bradley J, Govindan R, Meyers B
    Curr Probl Surg 2005 Aug;42(8):540-610
  • Chemotherapy for metastatic NSCLC: current status and future direction
    Govindan R
    Nat Clin Pract Oncol 2005 May;2(5):238-9
  • Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B
    Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL
    Clin Cancer Res 2005 Mar 15;11(6):2300-4
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B
    Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M
    Cancer 2005 Apr 15;103(8):1670-5
  • Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update
    Read W, McLeod H, Govindan R
    Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):15-7
  • Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status
    Govindan R, Garfield DH
    Semin Oncol 2004 Dec;31(6 Suppl 11):27-31
  • Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results
    Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, Hanna N, Stoner C, Ansari R, Fox E
    Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):18-21
  • Smoking urges and relapse among lung cancer patients: findings from a preliminary retrospective study
    Walker MS, Larsen RJ, Zona DM, Govindan R, Fisher EB
    Prev Med 2004 Sep;39(3):449-57
  • RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer
    Church RD, Yu J, Fleshman JW, Shannon WD, Govindan R, McLeod HL
    Br J Cancer 2004 Sep 13;91(6):1015-8
  • Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience
    Kommareddy A, Coplin MA, Gao F, Behnken D, Romvari E, Read W, Govindan R
    Lung Cancer 2004 Aug;45(2):221-5
  • Differential prognostic impact of comorbidity
    Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, Piccirillo JF
    J Clin Oncol 2004 Aug 1;22(15):3099-103
  • The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database
    Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R
    Lung Cancer 2004 Aug;45(2):137-42
  • Positron emission tomography in limited-stage small-cell lung cancer: a prospective study
    Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA
    J Clin Oncol 2004 Aug 15;22(16):3248-54
  • Novel agents in the treatment of lung cancer: conference summary statement
    Lynch TJ, Adjei AA, Bunn PA Jr, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS
    Clin Cancer Res 2004 Jun 15;10(12 Pt 2):4199s-4204s
  • Cetuximab in advanced non-small cell lung cancer
    Govindan R
    Clin Cancer Res 2004 Jun 15;10(12 Pt 2):4241s-4244s
  • Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC
    Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR
    Ann Oncol 2004 Mar;15(3):410-8
  • Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report
    Govindan R, Read W, Faust J, Trinkaus K, Ma MK, Baker SD, McLeod HL, Perry MC
    Oncology (Williston Park) 2003 Sep;17(9 Suppl 8):27-31
  • Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
    Fracasso PM, Rodriguez LC, Herzog TJ, Fears CL, Goodner SA, Govindan R, Picus J, Rader JS, Tan BR, Arquette MA
    Cancer 2003 Aug 1;98(3):610-7
  • Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib
    Govindan R, Behnken D, Read W, McLeod H
    Ann Oncol 2003 Aug;14(8):1330-1
  • Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer
    Govindan R, Read W, Faust J, Mc Leod H
    Oncology (Williston Park) 2003 Jul;17(7 Suppl 7):27-9
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response
    Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH
    Clin Cancer Res 2003 May;9(5):1728-33
  • In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM
    Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA
    Eur J Nucl Med Mol Imaging 2003 Jun;30(6):844-50
  • Management of patients with non-small cell lung cancer and poor performance status
    Govindan R
    Curr Treat Options Oncol 2003 Feb;4(1):55-9
  • Phase I study of rubitecan and gemcitabine in patients with advanced malignancies
    Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL
    Ann Oncol 2002 Nov;13(11):1819-25
  • Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation
    Arquette M, Wasserman T, Govindan R, Garfield D, Senzer N, Gillenwater H, Socinski M
    Semin Radiat Oncol 2002 Jan;12(1 Suppl 1):59-61
  • Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations
    Ortel TL, Moore KD, Quinn-Allen MA, Okamura T, Sinclair AJ, Lazarchick J, Govindan R, Carmagnol F, Kane WH
    Blood 1998 Jun 1;91(11):4188-96
  • Malignant hematopoietic breast tumors
    Lin Y, Govindan R, Hess JL
    Am J Clin Pathol 1997 Feb;107(2):177-86
  • Practical issues in the management of the patient with small cell lung cancer
    Govindan R, Ihde DC
    Chest Surg Clin N Am 1997 Feb;7(1):167-81
  • Treatable dementia in an elderly woman
    Govindan R, Das AK
    J Assoc Physicians India 1994 Jun;42(6):490
  • Cardiac autonomic function in fibrocalculous pancreatic diabetes
    Govindan R, Das AK
    Acta Diabetol 1993;30(1):36-8
  • Pregnancy and diabetes--review
    Das AK, Govindan R
    J Assoc Physicians India 1992 Nov;40(11):751-3
  • Fibrocalculous pancreatic diabetes in an elderly male
    Govindan R, Das AK
    J Assoc Physicians India 1992 Apr;40(4):280-1